OBALON THERAPEUTICS INC Human Resources Contracts & Agreements
38 Contracts & Agreements
- Bonus & Incentive Agreements (12 contracts)
- Compensation Agreements (1)
- Consulting Agreements (5)
- Employment Agreements (11)
- Retention Agreements (9)
- Consulting Agreement dated August 26, 2024 between Vyome Therapeutics, Inc. and Foresite Advisors, LLC (Filed With SEC on October 1, 2024)
- Employment Letter dated June 27, 2024 between Vyome Therapeutics, Inc. and Frank Wisner (Filed With SEC on October 1, 2024)
- Employment Agreement dated September 30, 2019 between Vyome Therapeutics, Inc. and Venkateswarlu Nelabhotla (Filed With SEC on October 1, 2024)
- Amendment to Employment Agreement, dated July 8, 2024, by and between ReShape Lifesciences Inc. and Paul F. Hickey (Filed With SEC on July 9, 2024)
- Executive Employment Agreement, dated October 29, 2019, by and between the Company and Thomas Stankovich (Filed With SEC on April 1, 2024)
- Executive Employment Agreement, dated October 29, 2019, by and between the Company and Thomas Stankovich (Filed With SEC on April 17, 2023)
- ReShape Lifesciences Inc. 2022 Equity Incentive Plan (Filed With SEC on December 20, 2022)
- Employment Agreement, dated November 1, 2022, between the Company and Paul F. Hickey (Filed With SEC on November 14, 2022)
- Retention Bonus Agreement, dated August 2, 2022, by and between the Company and Thomas Stankovich (Filed With SEC on August 2, 2022)
- Executive Employment Agreement, dated October 29, 2019, by and between the Company and Thomas Stankovich (Filed With SEC on April 8, 2022)
- Executive Employment Agreement, dated August 26, 2019, by and between the Company and Barton P. Bandy (Filed With SEC on April 8, 2022)
- Employment Agreement, dated as of October 29, 2019, by and between ReShape Lifesciences Inc. and Thomas Stankovich (Filed With SEC on March 30, 2021)
- Executive Employment Agreement, dated as of August 26, 2019, by and between ReShape Lifesciences Inc. and Barton Bandy (Filed With SEC on March 30, 2021)
- Executive Employment Agreement, dated as of May 22, 2017, by and between ReShape Lifesciences Inc. and Dr. Raj Nihalani (Filed With SEC on March 30, 2021)
- Form of Stock Option Grant Notice and Stock Option Agreement under ReShape Lifesciences Inc.s Second Amended and Restated 2003 Stock Incentive Plan (Filed With SEC on March 30, 2021)
- Second Amended and Restated 2003 Stock Incentive Plan of ReShape Lifesciences Inc., as amended on May 23, 2018 (Filed With SEC on March 30, 2021)
- Amendment to Amended and Restated Retention Agreement, dated as of January 18, 2021, by and between Obalon Therapeutics, Inc. and Nooshin Hussainy (Filed With SEC on March 12, 2021)
- Amendment and Restated Retention Agreement, dated as of January 18, 2021, by and between Obalon Therapeutics, Inc. and Andrew Rasdal (Filed With SEC on March 12, 2021)
- Amended and Restated 2016 Equity Incentive Plan and form award agreements thereunder (Filed With SEC on November 6, 2020)
- Consulting Agreement, dated August 11, 2020, between the Company and Blue Ox Healthcare Partners, LLC (Filed With SEC on August 14, 2020)
- Transition and Consulting Agreement, dated as of June 11, 2020, by and between Obalon Therapeutics, Inc. and Mark Brister (Filed With SEC on June 19, 2020)
- Transition and Consulting Agreement, dated as of June 11, 2020, by and between Obalon Therapeutics, Inc. and Amy Vandenberg (Filed With SEC on June 19, 2020)
- Amended and Restated Retention Agreement, dated as of June 9, 2020, by and between Obalon Therapeutics, Inc. and Nooshin Hussainy (Filed With SEC on June 19, 2020)
- Amended and Restated Retention Agreement, dated as of June 9, 2020, by and between Obalon Therapeutics, Inc. and Andrew Rasdal (Filed With SEC on June 19, 2020)
- Form of Restricted Stock Unit Award Agreement (Share and Cash Settlement) pursuant to the 2016 Equity Incentive Plan (Filed With SEC on February 27, 2020)
- Form of Restricted Stock Unit Award pursuant to the 2016 Equity Incentive Plan (Filed With SEC on February 27, 2020)
- Consulting Agreement dated May 20, 2019 between the Company and Kelly Huang (Filed With SEC on July 24, 2019)
- Form of Restricted Stock Unit Award pursuant to the 2016 Equity Incentive Plan (Filed With SEC on February 22, 2019)
- First Amendment to 2016 Equity Incentive Plan (Filed With SEC on February 22, 2019)
- Form of Executive Retention Agreement (Non-CEO) (April 2018) (Filed With SEC on May 10, 2018)
- OBALON THERAPEUTICS, INC. DIRECTOR COMPENSATION PROGRAM (EFFECTIVE APRIL 24, 2017) (Filed With SEC on August 2, 2017)
- NOTICE OF STOCK OPTION GRANT OBALON THERAPEUTICS INC. 2016 EQUITY INCENTIVE PLAN (Filed With SEC on February 23, 2017)
- Retention Agreement (Filed With SEC on November 10, 2016)
- Retention Agreement (Filed With SEC on November 10, 2016)
- RETENTION AGREEMENT (Filed With SEC on September 26, 2016)
- RETENTION AGREEMENT (Filed With SEC on September 26, 2016)
- OBALON THERAPEUTICS, INC. BONUS PLAN (Filed With SEC on September 26, 2016)
- OBALON THERAPEUTICS, INC. 2016 EQUITY INCENTIVE PLAN (Filed With SEC on September 26, 2016)
